前列腺癌患者同源重组修复缺陷的胚系与体细胞检测(上篇)
本专家共识由多学科专家组于2023至2024年制定,主张对所有前列腺癌患者广泛开展胚系检测,并在复发或转移性疾病时进行体细胞突变检测;上篇回顾基因组检测的实施方式及克服障碍将检测整合入临床实践的途径。
要点
- 主张对所有前列腺癌患者广泛开展胚系检测。
- 主张在复发或转移性疾病时进行体细胞突变检测。
- 上篇回顾基因组检测的实施及整合入临床实践的障碍克服。
核心结论
- 作者主张对所有前列腺癌患者广泛开展胚系检测,并在复发或转移性疾病时进行体细胞突变检测。
研究设计与样本
- 本指南由多学科专家组于2023至2024年制定,专家来自肿瘤内科、泌尿外科、放射肿瘤科、病理科、医学基因组学和基础科学。
主要发现
- 上篇回顾了基因组检测的实施方式以及克服将遗传和生物标志物检测整合入临床实践的某些障碍。
关键数值与推荐
- 主张对所有前列腺癌患者广泛开展胚系检测。
- 主张在复发或转移性疾病时进行体细胞突变检测。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND/OBJECTIVES: Unfortunately, not all metastatic castration resistant prostate cancer (mCRPC) patients receive available life-prolonging systemic therapies, emphasizing the need to optimize mCRPC treatment selections. Better guidelines are necessary to determine genetic testing in prostate cancer. SUBJECTS/METHODS: In this two-part expert opinion-based guide, we provide an expert consensus opinion on the utilization of germline and somatic testing to detect HRR alterations in patients with mCRPC. This guide was developed by a multidisciplinary expert panel that convened in 2023-2024, including representatives from medical oncology, urology, radiation oncology, pathology, medical genomics, and basic science. RESULTS/CONCLUSION: We argue for the widespread adoption of germline testing in all patients with prostate cancer and for somatic mutations testing in patients at the time of recurrent/metastatic disease. In this first part, we review how genomic testing is performed. We also review how to overcome certain barriers to integrate genetic and biomarker testing into clinical practice.
引用
- Armstrong AJ, Taylor A, Haffner MC, et al. Germline and somatic testing for homologous repair deficiency in patients with prostate cancer (part 1 of 2). Prostate Cancer Prostatic Dis. 2024. PMID: 39354185. doi:10.1038/s41391-024-00901-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。